How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

11,689 results for

Intrauterine Device

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

11581. Five years' experience with a small intracervical/intrauterine levonorgestrel-releasing device. (PubMed)

Five years' experience with a small intracervical/intrauterine levonorgestrel-releasing device. A randomized study was performed to compare the efficacy, safety and acceptability of a new model of an intracervical/intrauterine contraceptive device (ICD) releasing 20 microg of levonorgestrel (LNG) per day.The LNG-ICD was inserted in Group I into the cervical canal and in Group II into the uterine cavity. Group I included 151 women (age, 18-43 years) whereas Group II included 147 (age, 19-43 (...) and the Pearl rate 1.8 at 5 years. Also, the gross rate of infection was low (0.7). The continuation was high in spite of a high rate of removals for planning pregnancy (15.4).The method is safe and effective. There were only minor differences between the groups. There were no perforations and the incidence of infection was low. The device can also be used by young nulliparous women.

2005 Contraception Controlled trial quality: uncertain

11582. Cervical priming with sublingual misoprostol prior to insertion of an intrauterine device in nulliparous women: a randomized controlled trial. (PubMed)

Cervical priming with sublingual misoprostol prior to insertion of an intrauterine device in nulliparous women: a randomized controlled trial. The copper intrauterine device (IUD) is a highly effective and safe contraceptive method, also in nulliparous women. However, insertion of an IUD through a narrow cervix may be technically difficult. Misoprostol has been shown to be effective for cervical priming in non-pregnant women prior to hysteroscopy.Eighty nulliparous women requesting an IUD were

Full Text available with Trip Pro

2007 Human reproduction (Oxford, England) Controlled trial quality: predicted high

11583. A randomized trial of the intrauterine contraceptive device vs hormonal contraception in women who are infected with the human immunodeficiency virus. (PubMed)

A randomized trial of the intrauterine contraceptive device vs hormonal contraception in women who are infected with the human immunodeficiency virus. The purpose of this study was to determine whether the intrauterine contraceptive device (IUD) is effective and safe among women who are infected with the human immunodeficiency virus (HIV).We randomly assigned 599 postpartum, HIV-infected women in Zambia to receive either a copper IUD or hormonal contraception and followed them for at least 2

Full Text available with Trip Pro

2007 American journal of obstetrics and gynecology Controlled trial quality: uncertain

11584. [Random comparative study between intrauterine device Multiload Cu375 and TCu 380a inserted in the postpartum period]. (PubMed)

[Random comparative study between intrauterine device Multiload Cu375 and TCu 380a inserted in the postpartum period]. To evaluate safety and effectiveness of the intrauterine device Multiload Cu375 compared with the TCu 380A inserted in the postpartum period.In a randomized comparative study carried out in the National Perinatology Institute, intrauterine devices MLCu 375 and Tcu 380A were inserted to 157 patients who voluntary accepted, and previously signed informed consent. There were four (...) instances for the intrauterine devices insertion: within 10 minutes after vaginal delivery, during cesarean section (immediate postplacental insertion) and postpartum-postcesarean insertion (in the time range of 10 min to 48 h). All insertions were made with ring forceps. From 1 h to 24 h later, abdominal ultrasound examinations were performed to assess the distances between the upper part of the device to the fundus of uterine cavity. Follow up visits were scheduled at 3, 6, 9 and 12 months. Net

2006 Ginecología y obstetricia de México Controlled trial quality: uncertain

11585. Pain from copper intrauterine device insertion: randomized trial of prophylactic ibuprofen. (PubMed)

Pain from copper intrauterine device insertion: randomized trial of prophylactic ibuprofen. This study was undertaken to determine whether 400 mg of prophylactic ibuprofen can alleviate pain from insertion of an intrauterine device (IUD) and to measure level of pain with improved techniques.We conducted a randomized, double-blind, placebo-controlled trial of 2019 first-time IUD users: 1008 women received placebo and 1011 women received 400 mg of ibuprofen. Participants took the single tablet

2006 American journal of obstetrics and gynecology Controlled trial quality: predicted high

11586. Can nurses who are trained in the fitting of intrauterine devices, who are also extended independent prescribers, prescribe Mirena (Levonorgestrel releasing intrauterine system)?

Can nurses who are trained in the fitting of intrauterine devices, who are also extended independent prescribers, prescribe Mirena (Levonorgestrel releasing intrauterine system)? Can nurses who are trained in the fitting of intrauterine devices, who are also extended independent prescribers, prescribe Mirena (Levonorgestrel releasing intrauterine system)? - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY (...) in the fitting of intrauterine devices, who are also extended independent prescribers, prescribe Mirena (Levonorgestrel releasing intrauterine system)? Information on the Nurse Prescriber’s Extended Formulary [NPEF] contained on the PRODIGY website states: “ EFNPs [Extended Formulary Nurse Prescribers] should restrict their prescribing to the treatment of the medical conditions specified in the NPEF. They should NOT prescribe independently outside these conditions. EFNPs may prescribe any GSL or P medicine

2006 TRIP Answers

11587. Can a woman with a levonorgestrel-releasing intrauterine system in situ start treatment of Dianette for hirsuitism (related to poly cystic ovarian syndrome) without removing her intrauterine device re

Can a woman with a levonorgestrel-releasing intrauterine system in situ start treatment of Dianette for hirsuitism (related to poly cystic ovarian syndrome) without removing her intrauterine device re Can a woman with a levonorgestrel-releasing intrauterine system in situ start treatment of Dianette for hirsuitism (related to poly cystic ovarian syndrome) without removing her intrauterine device removed? - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title (...) @tripdatabase.com Can a woman with a levonorgestrel-releasing intrauterine system in situ start treatment of Dianette for hirsuitism (related to poly cystic ovarian syndrome) without removing her intrauterine device removed? We were unable to find a suitable answer, so contact the Faculty of Family Practice and Reproductive Health Care ( ) who supplied the following answer [1]: “Polycystic ovary syndrome (PCOS) affects around 5% to 10% of women. It is characterised by hyperandrogenism, chronic anovulation

2007 TRIP Answers

11588. Intrauterine devices and pelvic inflammatory disease: an international perspective. (PubMed)

Intrauterine devices and pelvic inflammatory disease: an international perspective. The risk of pelvic inflammatory disease (PID) associated with use of an intrauterine device (IUD) has been an important concern that has dominated decisions on its use throughout the world, especially in the USA. Early research that suggested such an association led to both a dramatic decline in use of the method and its withdrawal from the US market by two manufacturers. However, factors other than use (...) is an infrequent event beyond the first 20 days after insertion. Because of this increased risk with insertion, IUDs should be left in place up to their maximum lifespan and should not routinely be replaced earlier, provided there are no contraindications to continued use and the woman wishes to continue with the device.

1992 Lancet

11589. Use of copper intrauterine devices and the risk of tubal infertility among nulligravid women. (PubMed)

Use of copper intrauterine devices and the risk of tubal infertility among nulligravid women. Previous studies of intrauterine devices (IUDs), many of which are no longer in use, suggested that they might cause tubal infertility. The concern that IUDs that contain copper--currently the most commonly used type--may increase the risk of infertility in nulligravid women has limited the use of this highly effective method of birth control.We conducted a case-control study of 1895 women recruited

2001 NEJM

11590. Randomised controlled trial of prophylactic antibiotics before insertion of intrauterine devices. IUD Study Group. (PubMed)

Randomised controlled trial of prophylactic antibiotics before insertion of intrauterine devices. IUD Study Group. The value of antibiotic prophylaxis before insertion of an intrauterine device (IUD) remains uncertain. We undertook a triple-masked, randomised, placebo-controlled trial to find out whether such prophylaxis reduces the rate of IUD removal within 90 days.11 clinic sites in southern California enrolled women who requested IUD insertion and were at low risk of sexually transmitted

1998 Lancet Controlled trial quality: predicted high

11591. A novel device for removal of the retained intrauterine device. (PubMed)

A novel device for removal of the retained intrauterine device. To evaluate the efficacy and acceptability of the Macaluso stent removal forceps for removal of retained intrauterine devices (IUDs) under direct vision using a hysteroscope in an outpatient setting.Nineteen consecutive patients with a retained IUD who had been referred from primary care to the gynaecologists at the Conquest Hospital, Hastings, UK were included in the study. Attempts were made to remove the IUDs under direct vision (...) using the Gynecare Versascope and Macaluso forceps.The procedure was successful in 18/19 (94.7%) patients. The patients tolerated the procedure well and none of them complained of severe pain.This device is simple, safe, effective and acceptable for the removal of IUDs with lost threads.

Full Text available with Trip Pro

2006 Journal of Family Planning and Reproductive Health Care

11592. Anesthetic Efficacy of Intrauterine Lidocaine for Removal of a "Lost" Intrauterine Device

Anesthetic Efficacy of Intrauterine Lidocaine for Removal of a "Lost" Intrauterine Device Anesthetic Efficacy of Intrauterine Lidocaine for Removal of a "Lost" Intrauterine Device - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more (...) studies before adding more. Anesthetic Efficacy of Intrauterine Lidocaine for Removal of a "Lost" Intrauterine Device The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00308841 Recruitment Status : Completed First Posted : March 30, 2006 Last Update Posted : October 20, 2008 Sponsor: Suleyman Demirel

2006 Clinical Trials

11593. Copper-T intrauterine device and levonorgestrel intrauterine system: biological bases of their mechanism of action. (PubMed)

Copper-T intrauterine device and levonorgestrel intrauterine system: biological bases of their mechanism of action. All intrauterine devices (IUDs) that have been tested experimentally or clinically induce a local inflammatory reaction of the endometrium whose cellular and humoral components are expressed in the tissue and the fluid filling the uterine cavity. Depending on the reproductive strategy of the species considered and the anatomical features and physiologic mechanisms

2007 Contraception

11594. Assessment of workload: intrauterine device/intrauterine system provision. (PubMed)

Assessment of workload: intrauterine device/intrauterine system provision. The Faculty of Family Planning and Reproductive Health Care (FFPRHC) has recently published Service Standards for Workload in Contraception, which state that a minimum of 20 minutes should be made available for intrauterine device/hormonal system (IUD/IUS) provision. This document acknowledges that there is currently little formal evidence relating to assessment of time taken for providing various contraceptive methods

Full Text available with Trip Pro

2006 Journal of Family Planning and Reproductive Health Care

11595. Training to fit intrauterine devices/intrauterine systems for general practitioners: is there an alternative method of service delivery? (PubMed)

Training to fit intrauterine devices/intrauterine systems for general practitioners: is there an alternative method of service delivery? This paper questions the traditional method of obtaining intrauterine device (IUD) and intrauterine system (IUS) training, by highlighting the pitfalls of this training, and introduces community IUD/IUS training, a new model offering significant advantages.Traditional IUD/IUS training is not optimal for a variety of reasons including scarcity of designated IUD

Full Text available with Trip Pro

2007 Journal of Family Planning and Reproductive Health Care

11596. Efficacy of intrauterine lidocaine for removal of a "lost" intrauterine device: a randomized, controlled trial. (PubMed)

Efficacy of intrauterine lidocaine for removal of a "lost" intrauterine device: a randomized, controlled trial. To evaluate the efficacy of intrauterine lidocaine instillation in reducing patient discomfort during the removal of a "lost" intrauterine device (IUD).This double-blinded, randomized, placebo-controlled trial included 68 women who underwent removal procedure for a "lost" IUD. Thirty-four women were allocated to the lidocaine group and 34 to the saline group. The main outcome measure (...) , and duration of IUD. Pain scores demonstrated a significant difference between groups during the procedure (placebo 6.41 +/- 1.15, lidocaine 5.23 +/- 0.69, P < .01), immediately after procedure (placebo 6.05 +/- 1.01, lidocaine 4.94 +/- 0.60, P < .01), and 20 minutes after procedure (placebo 4.32 +/- 0.63, lidocaine 4.44 +/- 0.66, P < .01). The number needed to treat was 3 (95% confidence interval 2-9).Intrauterine lidocaine appears to be effective in decreasing pain in women undergoing the removal

Full Text available with Trip Pro

2006 Obstetrics and Gynecology Controlled trial quality: predicted high

11597. A comparative study of the levonorgestrel-releasing intrauterine system Mirena versus the Copper T380A intrauterine device during lactation: breast-feeding performance, infant growth and infant development. (PubMed)

A comparative study of the levonorgestrel-releasing intrauterine system Mirena versus the Copper T380A intrauterine device during lactation: breast-feeding performance, infant growth and infant development. Mirena is a levonorgestrel-releasing intrauterine system (LNG-IUS) that provides highly effective and long-acting progestogen-only contraception.The objective of this study was to analyze the possible effects of using LNG-20 microg IUS on breast-feeding performance, infant growth and infant (...) development during the first postpartum year as compared with the Copper T380A intrauterine device (Cu T380A IUD).This study is a prospective, controlled and randomized trial.The study was conducted at the Department of Obstetrics and Gynecology, Assiut University Hospital, Egypt.Three hundred twenty lactating women asking for initiation of contraception during the early postpartum stage were assigned randomly into two groups, the LNG-20 microg IUS group (n=163) and the Cu T380A group (n=157

2005 Contraception Controlled trial quality: uncertain

11598. Management of Intrauterine Device-Associated Actinomycosis (PubMed)

Management of Intrauterine Device-Associated Actinomycosis To assess various methods of management of actinomyces-like organisms associated with intrauterine devices.A retrospective chart review of 173 patients with intrauterine device-associated actinomyces- like organisms detected on Pap smear was performed. The patients were managed by IUD removal with or without antibiotic therapy, antibiotic therapy alone, or no treatment at all.The success rate as reflected in negative follow-up smear (...) was 100% for IUD removal combined with antibiotics, 97.4% for IUD removal alone, and 36.8% for antibiotics therapy alone.The best way to manage intrauterine device-associated actinomyces-like organisms is removal of the device with or without antibiotics.

Full Text available with Trip Pro

1993 Infectious diseases in obstetrics and gynecology

11599. Intrauterine devices and pelvic inflammatory disease--a reanalysis of the literature. (PubMed)

Intrauterine devices and pelvic inflammatory disease--a reanalysis of the literature. 2028601 1991 06 12 2018 11 13 0093-0415 154 3 1991 Mar The Western journal of medicine West. J. Med. Intrauterine devices and pelvic inflammatory disease--a reanalysis of the literature. 328-9 Beck E E eng Journal Article United States West J Med 0410504 0093-0415 AIM IM Female Humans Intrauterine Devices Pelvic Inflammatory Disease etiology 1991 3 1 1991 3 1 0 1 1991 3 1 0 0 ppublish 2028601 PMC1002763 Fertil

Full Text available with Trip Pro

1991 Western Journal of Medicine

11600. Was the Dalkon Shield a safe and effective intrauterine device? The conflict between case-control and clinical trial study findings. (PubMed)

Was the Dalkon Shield a safe and effective intrauterine device? The conflict between case-control and clinical trial study findings. To compare the findings of the case-control and cohort studies used to indict the Dalkon Shield (A.H. Robins Company, Inc., Richmond, VA) with the findings of the Dalkon Shield clinical trials.All published reports on the Dalkon Shield were identified through MEDLARS system (United States National Library of Medicine) searches and by cross checking all references (...) in these reports. The same approach was used to identify all case-control and cohort studies of the purported relationship between intrauterine devices (IUDs) and pelvic inflammatory disease (PID).Only studies of interval patients that included 50 or more women and 6 or more months of follow up that computed standard IUD event rates (rates of pregnancy and expulsion and removal for pain and bleeding) were selected for this study. All case-control and cohort studies identified were included except two case

1992 Fertility and sterility

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>